clinical trial · NCT04976153
Skeletal Muscle-derived Cell Implantation for Treatment of Fecal Incontinence
Fecal IncontinenceaSMDCPlacebo
brief summary
The objective of this study is the final assessment of clinical safety and efficacy of autologous autologous skeletal muscle derived cells for patients with urge fecal incontinence due to external anal sphincter dysfunction caused by its disruption and/or weakness.
started
May 11, 2022
primary completion
Mar 31, 2027
completion
Jul 31, 2027
last updated
Mar 12, 2025
official title
Skeletal Muscle-derived Cell Implantation for the Treatment of Fecal Incontinence: a Phase III, Randomized, Controlled, Double Blind, Two Armed Clinical Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol